| Literature DB >> 24352026 |
Chun Li, Wen Yang, Huanhuan Liu, Mengying Li, Weiqun Zhou1, Juan Xie.
Abstract
Ni(II) complexes with N-2-fluorobenzoylpiperidine-1-carbothioimidate (L2-), N-4-fluorobenzoylpiperidine-1-carbothioimidate (L3-), N-2-fluorobenzoylmorpholine- 1-carbothioimidate (L5-) and N-4-fluorobenzoylmorpholine-1-carbothioimidate (L6-) have been synthesized and characterized by elemental analysis, FTIR and 1H-NMR. The crystal structures of three ligands (HL2, HL3 and HL6) and the corresponding Ni(II) complexes ([Ni(L2)2], [Ni(L3)2] and [Ni(L6)2]) have been determined by X-ray diffraction. The antifungal activities of the Ni(II) complexes together and the corresponding ligands against the fungi Botrytis cinerea, Trichoderma spp., Myrothecium and Verticillium spp. have been investigated. The experimental results showed that the ligands and their complexes have antifungal abilities. When the fluorine was substituted on the para-benzoyl moiety, the antifungal activity of the ligands was obviously increased. Moreover, the ligands were stronger than their complexes in inhibiting fungal activities. The antifungal ability of HL6 is especially strong, and similar to that of the commercial fungicide fluconazole.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24352026 PMCID: PMC6270642 DOI: 10.3390/molecules181215737
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Molecular structures of HL2 and [Ni(L2)2], with thermal ellipsoids drawn at 40% probability.
Figure 2Molecular structures of HL3 and [Ni(L3)2], with thermal ellipsoids drawn at 40% probability.
Figure 3Molecular structures of HL6 and [Ni(L6)2] with thermal ellipsoids drawn at 40% probability.
Summary of X-ray diffraction data.
| Parameter | HL2 | [Ni(L2)2] | HL3 | [Ni(L3)2] | HL6 | [Ni(L6)2] |
|---|---|---|---|---|---|---|
| Empirical formula | C13H15FN2OS | C26H28F2N4NiO2S2 | C13H15FN2OS | C26H28F2N4NiO2S2 | C12H13FN2O2S | C24H24F2N4NiO4S2 |
| Formula weight | 266.33 | 589.35 | 266.33 | 589.35 | 268.3 | 593.3 |
| Crystal system | Monoclinic | Orthorhombic | Triclinic | Triclinic | Monoclinic | Triclinic |
| Space group |
|
|
|
|
|
|
| a (Å) | 11.843(3) | 11.6111(17) | 8.3759(15) | 9.5530(16) | 21.214(6) | 9.3383(6) |
| b (Å) | 13.282(3) | 9.8778(17) | 11.191(2) | 11.890(2) | 9.7391(16) | 11.5273(9) |
| c (Å) | 8.432(2) | 45.925(7) | 13.960(3) | 12.548(2) | 14.637(7) | 12.7230(8) |
| α (°) | 90 | 90 | 89.981(10) | 104.350(4) | 90 | 105.206(6) |
| β (°) | 108.474(5) | 90 | 89.969(10) | 100.377(3) | 125.91(3) | 101.420(5) |
| γ (°) | 90 | 90 | 79.699(9) | 97.110(4) | 90 | 96.112(6) |
| Z | 4 | 8 | 4 | 2 | 8 | 2 |
| Dcalc (g/cm3) | 1.406 | 1.486 | 1.374 | 1.464 | 1.455 | 1.543 |
| Radiation (MoKα) (Å) | 0.71075 | 0.7107 | 0.7107 | 0.7107 | 0.71075 | 0.71073 |
| μ(Mo Kα) (mm−1) | 0.259 | 0.941 | 0.253 | 0.927 | 0.272 | 0.977 |
| θ Range (°) | 3.03 to 27.50 | 3.02 to 25.35 | 3.17 to 25.34 | 3.01 to 25.35 | 3.34 to 27.50 | 3.03 to 26.37 |
| Reflections collected | 7538 | 34,645 | 12,652 | 12,987 | 10,790 | 13,024 |
| Independent reflections | 2850 | 4799 | 4678 | 4872 | 2773 | 5220 |
| R(int) | 0.022 | 0.0687 | 0.0719 | 0.0292 | 0.0514 | 0.0208 |
| Data | 2850 | 4799 | 4678 | 4872 | 2773 | 5220 |
| restraints | 0 | 0 | 2 | 0 | 0 | 17 |
| Parameters | 165 | 344 | 334 | 335 | 163 | 334 |
| GOF on F2 | 1.011 | 1.009 | 1.098 | 1.079 | 0.999 | 1.023 |
| R1 [I > 2sigma(I)] | 0.0436 | 0.0904 | 0.0838 | 0.0536 | 0.0422 | 0.0406 |
| wR2 [I > 2sigma(I)] | 0.1141 | 0.1785 | 0.1771 | 0.1242 | 0.1084 | 0.1002 |
| R1 [all data] | 0.0551 | 0.11 | 0.1575 | 0.0723 | 0.0636 | 0.0564 |
| wR2 [all data] | 0.1222 | 0.1892 | 0.2080 | 0.1353 | 0.1190 | 0.1105 |
| Largest difference peak (e.A−3) | 0.362 and −0.377 | 0.728 and −0.413 | 0.265 and −0.316 | 0.627 and −0.297 | 0.331 and −0.449 | 0.552 and −0.315 |
The MIC of the ligands and their complexes against the studied fungi (SD: standard deviation).
| Samples |
|
| ||
|---|---|---|---|---|
| Fluconazoleole | 7.0 ± 0.1 | 8.0 ± 0.1 | 7.5 ± 0.1 | 7.5 ± 0.1 |
| HL1 | 31.0 ± 0.0 | 22.5 ± 0.1 | 32.5 ± 0.1 | 34.0 ± 0.0 |
| [Ni(L1)2] | 33.0 ± 0.0 | 31.5 ± 0.1 | 36.0 ± 0.0 | 38.0 ± 0.1 |
| HL2 | 27.5 ± 0.0 | 29.0 ± 0.0 | 27.5 ± 0.1 | 28.0 ± 0.0 |
| [Ni(L2)2] | 31.0 ± 0.1 | 33.0 ± 0.1 | 31.0 ± 0.1 | 31.5 ± 0.1 |
| HL3 | 20.5 ± 0.1 | 18.0 ± 0.1 | 22.5 ± 0.1 | 25.0 ± 0.0 |
| [Ni(L3)2] | 22.5 ± 0.0 | 31.0 ± 0.0 | 29.0 ± 0.1 | 31.0 ± 0.0 |
| HL4 | 2.5 ± 0.1 | 2 ± 0.0 | 2.3 ± 0.0 | 0.8 ± 0.1 |
| [Ni(L4)2] | 29.0 ± 0.1 | 32.5 ± 0.1 | 35.5 ± 0.1 | 35.5 ± 0.1 |
| HL5 | 31.0 ± 0.1 | 27.5 ± 0.0 | 27.5 ± 0.0 | 31.0 ± 0.1 |
| [Ni(L5)2] | 32.5 ± 0.1 | 31.0 ± 0.1 | 31.0 ± 0.1 | 31.5 ± 0.0 |
| HL6 | 8.0 ± 0.0 | 8.5 ± 0.0 | 7.0 ± 0.1 | 8.5 ± 0.0 |
| [Ni(L6)2] | 31.0 ± 0.0 | 25.0 ± 0.0 | 27.5 ± 0.1 | 27.5 ± 0.0 |
Some structure parameters of the determined crystals
| Distances (Å) | HL2 | [Ni(L2)2] | HL3 | [Ni(L3)2] | HL6 | [Ni(L6)2] |
|---|---|---|---|---|---|---|
| Ni(1)-O(1) | 1.859 (4) | 1.864 (2) | 1.861 (18) | |||
| Ni(1)-O(2) | 1.846 (4) | 1.866 (2) | 1.864 (18) | |||
| Ni(1)-S(1) | 2.130 (2) | 2.140 (11) | 2.145 (8) | |||
| Ni(1) -S(2) | 2.147 (2) | 2.139 (11) | 2.142 (8) | |||
| S(1)-C(8) | 1.673 (15) | 1.728 (7) | 1.668 (5) | 1.742 (4) | 1.679 (2) | 1.737 (2) |
| S(2)-C(21) | 1.723 (6) | 1.666 (5) | 1.731 (4) | |||
| S(2)-C(20) | 1.731 (3) | |||||
| O(1)-C(1) | 1.215 (19) | 1.271 (7) | 1.233 (5) | 1.275 (4) | 1.219 (2) | 1.268 (3) |
| O(2)-C(14) | 1.269 (7) | 1.233 (6) | 1.268 (4) | |||
| O(2)-C(13) | 1.272 (3) | |||||
| N(1)-C(1) | 1.378 (18) | 1.319 (7) | 1.358 (6) | 1.312 (4) | 1.392 (2) | 1.321 (3) |
| N(3)-C(14) | 1.309 (7) | 1.358 (6) | 1.319 (5) | |||
| N(3)-C(13) | 1.307 (3) | |||||
| N(1)-C(8) | 1.413 (19) | 1.337 (8) | 1.434 (6) | 1.340 (5) | 1.397 (2) | 1.342 (3) |
| N(3)-C(21) | 1.341 (8) | 1.430 (6) | 1.334 (5) |
Figure 4The packing diagrams of the corresponding hydrogen bonds of ligands.
Scheme 1Synthetic route of the ligands and the complexes.